Belantamab mafodotin associated corneal microcyst-like epithelial changes
| dc.contributor.author | Chuang, Katherine | |
| dc.contributor.author | Pineda, Roberto | |
| dc.contributor.author | Liu, Shaohui | |
| dc.contributor.department | Ophthalmology, School of Medicine | en_US |
| dc.date.accessioned | 2023-05-02T15:44:45Z | |
| dc.date.available | 2023-05-02T15:44:45Z | |
| dc.date.issued | 2022-02-02 | |
| dc.description.abstract | Purpose: To report a case of bilateral corneal microcyst-like epithelial changes associated with belantamab mafodotin (belamaf) therapy. Observations: A 70-year-old man with refractory multiple myeloma was placed on belamaf, a recently FDA-approved treatment for relapsed or refractory multiple myeloma. He developed decreased visual acuity and bilateral corneal microcyst-like peripheral epithelial changes. Belamaf was withheld.Anterior segment OCT showed intra-epithelial opacities at various depths. After resolution of corneal changes and recovery of vision, belamaf was restarted. The patient underwent two additional treatments, each time with recurrence of diffuse microcyst-like corneal epithelial changes. It took a total of 8, 11.5 and 17 weeks after each respective infusion for the microcyst-like epithelial changes to resolve. This suggested a longer recovery time after each subsequent infusion. Conclusions and importance: The care for patients on belamaf requires the collaboration of eye care providers and hematologists-oncologists to assess for ocular adverse effects and adjust treatment as necessary. Further study is needed to illustrate the mechanism of corneal microcyst-like epithelial changes and its effects on limbal stem cells. | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.identifier.citation | Chuang K, Pineda R, Liu S. Belantamab mafodotin associated corneal microcyst-like epithelial changes. Am J Ophthalmol Case Rep. 2022;25:101392. Published 2022 Feb 2. doi:10.1016/j.ajoc.2022.101392 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/32769 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.isversionof | 10.1016/j.ajoc.2022.101392 | en_US |
| dc.relation.journal | American Journal of Ophthalmology Case Reports | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.source | PMC | en_US |
| dc.subject | Belantamab mafodotin | en_US |
| dc.subject | Cornea | en_US |
| dc.subject | Drug adverse effects | en_US |
| dc.title | Belantamab mafodotin associated corneal microcyst-like epithelial changes | en_US |
| dc.type | Article | en_US |